Physician profile
William Chen
NPI 1851498372
$7,702.77
in general payments reported to CMS, 2019-2025
30 companies · $949 in 2025
The $949 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $2,714 · 2021: $1,488 · 2022: $742 · 2023: $662 · 2024: $726 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.86 |
| Education | $147.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,831.80 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Amarin Pharma, INC. | $1,230.72 | 2020-2021 | |
| Pfizer INC. | $1,128.86 | 2019-2024 | |
| Novo Nordisk INC | $769.39 | 2019-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $499.96 | 2023-2025 | Gemtesa |
| Abbvie INC. | $329.14 | 2019-2025 | Creon, Linzess |
| Sunovion Pharmaceuticals INC. | $326.09 | 2020-2022 | |
| Amgen INC. | $289.93 | 2019-2020 | |
| Astellas Pharma US INC | $178.35 | 2023-2024 | Veozah, Myrbetriq |
| Madrigal Pharmaceuticals | $177.13 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $162.46 | 2020 | |
| Lilly USA, LLC | $155.31 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.86 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $69.55 | 2019-2020 | |
| Allergan, INC. | $61.94 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $50.79 | 2020 | |
| Janssen Pharmaceuticals, INC | $44.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $38.54 | 2020 | |
| Philips North America LLC | $32.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.30 | 2020 | |
| Merck Sharp & Dohme LLC | $27.81 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.88 | 2019-2022 | |
| Radius Health, INC. | $25.01 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $24.56 | 2021 | |
| Genzyme Corporation | $21.89 | 2020 | |
| Roche Diagnostics Corporation | $21.72 | 2019 | |
| Portola Pharmaceuticals, LLC | $18.10 | 2019 | |
| Ardelyx, INC. | $15.89 | 2025 | Ibsrela |
| Electromed, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.